MXPA03003960A - Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders. - Google Patents

Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders.

Info

Publication number
MXPA03003960A
MXPA03003960A MXPA03003960A MXPA03003960A MXPA03003960A MX PA03003960 A MXPA03003960 A MX PA03003960A MX PA03003960 A MXPA03003960 A MX PA03003960A MX PA03003960 A MXPA03003960 A MX PA03003960A MX PA03003960 A MXPA03003960 A MX PA03003960A
Authority
MX
Mexico
Prior art keywords
pentamidine
chlorpromazine
drugs
combinations
treatment
Prior art date
Application number
MXPA03003960A
Other languages
Spanish (es)
Inventor
Brent R Stockwell
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of MXPA03003960A publication Critical patent/MXPA03003960A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) chlorpromazine or a metabolite or analog thereof; and (ii) pentamidine or a metabolite or analog thereof simultaneously or within 14 days of each other in amounts sufficient to inhibit the growth of the neoplasm.
MXPA03003960A 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders. MXPA03003960A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/706,929 US6569853B1 (en) 2000-11-06 2000-11-06 Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
PCT/US2001/047959 WO2002058684A2 (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders

Publications (1)

Publication Number Publication Date
MXPA03003960A true MXPA03003960A (en) 2004-09-10

Family

ID=24839666

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003960A MXPA03003960A (en) 2000-11-06 2001-10-30 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders.

Country Status (29)

Country Link
US (4) US6569853B1 (en)
EP (1) EP1339399B1 (en)
JP (1) JP2004517915A (en)
KR (1) KR100720205B1 (en)
CN (1) CN1484525A (en)
AR (1) AR035500A1 (en)
AT (1) ATE318590T1 (en)
AU (1) AU2002246636B8 (en)
BG (1) BG107831A (en)
BR (1) BR0115166A (en)
CA (1) CA2436799C (en)
CY (1) CY1105501T1 (en)
DE (1) DE60117615T2 (en)
DK (1) DK1339399T3 (en)
EE (1) EE200300212A (en)
ES (1) ES2258566T3 (en)
HR (1) HRP20030460A2 (en)
HU (1) HUP0400529A3 (en)
IL (1) IL155795A0 (en)
IS (1) IS2457B (en)
MX (1) MXPA03003960A (en)
NO (1) NO20032036L (en)
NZ (1) NZ525773A (en)
PL (1) PL362690A1 (en)
PT (1) PT1339399E (en)
RU (1) RU2286769C2 (en)
SK (1) SK5452003A3 (en)
TW (1) TWI259077B (en)
WO (1) WO2002058684A2 (en)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1231910E (en) * 1999-11-16 2009-08-06 Oncozyme Pharma Inc Pentamidine for treating cancer
DE10015818A1 (en) * 2000-03-30 2001-10-18 Infineon Technologies Ag Biosensor and method for determining macromolecular biopolymers using a biosensor
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
EP1360180A1 (en) * 2001-01-19 2003-11-12 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
WO2002069949A2 (en) * 2001-03-06 2002-09-12 Prendergast Patrick T Combination therapy for reduction of toxycity of chemotherapeutic agents
WO2002096412A1 (en) * 2001-05-31 2002-12-05 The Cleveland Clinic Foundation Ptpase inhibitors and method of using same
FR2825279B1 (en) * 2001-06-01 2005-04-08 Molecular Engines Lab USEFUL MEDICINE IN THE TREATMENT OF CANCER
US20040010045A1 (en) * 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
US20050215629A1 (en) * 2001-09-07 2005-09-29 Taolin Yi PTPase inhibitors and methods of using the same
EP1572070A4 (en) * 2001-09-07 2009-11-04 Cleveland Clinic Foundation Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
AU2004201240B2 (en) * 2001-09-27 2008-08-07 Bar Ilan University Conjugated Psychotropic Drugs and Uses Thereof
US8053477B2 (en) * 2002-03-29 2011-11-08 University Of Maryland, Baltimore Inhibitors of the S100-p53 protein-protein interaction and method of inhibiting cancer employing the same
AU2003241346A1 (en) * 2002-05-01 2003-11-17 The Cleveland Clinic Foundation Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
BR0312597A (en) * 2002-07-11 2005-05-10 Combinatorx Inc Drug Combinations for the Treatment of Neoplasms
DE602004027014D1 (en) * 2003-03-26 2010-06-17 Synergy Biosystems Ltd TTEL AND SYNERGISTIC COMBINATIONS
US8071645B2 (en) * 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
BRPI0414568A (en) * 2003-09-18 2006-11-07 Combinatorx Inc drug combinations for the treatment of neoplasms
TW200526777A (en) * 2003-11-12 2005-08-16 Combinatorx Inc Combinations for the treatment of proliferative diseases
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
ATE532517T1 (en) 2003-11-13 2011-11-15 Noa Sic Aps THIORIDAZINE AND ITS DERIVATIVES FOR REVERTING ANTIMICROBIAL DRUG RESISTANCE
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
ES2629682T3 (en) 2004-03-29 2017-08-14 University Of South Florida Effective treatment of tumors and cancer with triciribin phosphate
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CN1976723B (en) 2004-04-30 2010-12-29 Bkg制药有限公司 Use of preparing medicine for treating or preventing infectious diseases
WO2005117847A2 (en) * 2004-06-02 2005-12-15 Combinatorx, Incorporated Methods and compounds for the treatment of neoplasms
CA2595156A1 (en) * 2005-01-19 2006-07-27 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
AU2006239896A1 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
EP1877047A2 (en) * 2005-05-02 2008-01-16 The Regents of the University of Colorado Systems and methods for treating human inflammatory and proliferative diseases, with a combination of compounds, or a bifunctional compound,that provides fatty acid metabolism and glycolysis inhibition
US9233094B2 (en) * 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
DE102005024017A1 (en) * 2005-05-25 2006-11-30 Merck Patent Gmbh quinazolinones
US20090298814A1 (en) * 2005-06-07 2009-12-03 Ramot At Tel Aviv Univeristy Ltd Novel salts of conjugated psychotropic drugs and processes of preparing same
CN1870631B (en) * 2005-11-11 2010-04-14 华为技术有限公司 Gate control method of media gateway
US20070202079A1 (en) * 2006-01-11 2007-08-30 Taolin Yi Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
RU2448697C2 (en) 2006-03-22 2012-04-27 Медигене Аг Treating three receptor negative breast cancer
WO2007149381A2 (en) * 2006-06-19 2007-12-27 The Cleveland Clinic Foundation Compositions comprising a ptp-ase inhibitor and use thereof in treating cancer
US20080226596A1 (en) * 2006-06-19 2008-09-18 Taolin Yi Therapeutic compositions and methods useful in treating hepatitis
AU2007274583B2 (en) * 2006-07-17 2012-11-01 Bar-Ilan University Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
MX2009007235A (en) * 2007-01-05 2009-10-16 Bkg Pharma Aps Low-carbohydrate milk with original calcium.
EP2124857B1 (en) * 2007-01-09 2017-03-29 Fovea Pharmaceuticals Apparatus for intra-ocular injection
DE102007013855A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituted tetrahydroquinolines
DE102007013856A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituted tetrahydropyrroloquinolines
DE102007013854A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydroquinolines
US20110009351A1 (en) * 2007-05-09 2011-01-13 Traffick Therepeutics Inc. Screening assay to identify correctors of protein trafficking defects
CN101138558B (en) * 2007-09-13 2010-08-25 汕头大学医学院 Pentamidine and death domain receptor ligand united application
ATE534389T1 (en) * 2007-10-05 2011-12-15 Univ Mons Hainaut BISBENZIMIDAZOLE AND ANTIMALARIA DRUGS
WO2009101616A1 (en) * 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
US20100035858A1 (en) * 2008-07-18 2010-02-11 Immune Control, Inc. Novel Compositions and Methods for Binding and Inhibiting 5-HT4 Receptor
US9034389B2 (en) 2009-03-11 2015-05-19 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
US8993625B2 (en) 2009-03-11 2015-03-31 Stable Solutions Llc Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle
CA2758856A1 (en) * 2009-05-01 2010-11-04 Oncozyme Pharma Inc. Pentamidine combinations for treating cancer
CN102439453A (en) 2009-05-20 2012-05-02 日内瓦大学 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
WO2011035225A1 (en) * 2009-09-21 2011-03-24 President And Fellows Of Harvard College Synergistic combination therapy
AU2010329440A1 (en) * 2009-12-09 2012-08-09 Bar-Ilan University Methods of improving cognitive functions
WO2011133966A2 (en) * 2010-04-23 2011-10-27 University Of Florida Research Foundation,Inc. Method and compositions for treating ace2-related disorders
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
SI2550963T1 (en) * 2011-07-25 2017-05-31 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidoxime carboxylic acid esters of pentamidine as prodrugs and their use as medicament
AU2012292016B2 (en) * 2011-08-02 2017-06-01 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Selective inhibition MALT1 protease by phenothiazine derivatives
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
US9375411B2 (en) 2012-12-21 2016-06-28 Verlyx Pharma Inc. Uses and methods for the treatment of liver diseases or conditions
RU2530651C1 (en) * 2013-11-06 2014-10-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Agent possessing anti-inflammatory and antifibrotic action in pulmonary tissue, and cytostatic action
KR101538264B1 (en) * 2014-01-24 2015-07-20 계명대학교 산학협력단 Pharmaceutical composition for preventing or treating cancer comprising thioridazine and TRAIL
CN105255887B (en) * 2015-07-17 2018-05-18 四川大学 A kind of recombinant slow virus and its purposes in the drug for preparing treatment cocaine habituation
WO2020082037A1 (en) * 2018-10-19 2020-04-23 Auransa Inc. Methods for treating a subtype of small cell lung cancer
CN109793727A (en) * 2019-03-13 2019-05-24 湖北科技学院 A kind of pharmaceutical composition and its application of effective anti-malignant tumor
KR102562739B1 (en) * 2020-09-11 2023-08-03 연세대학교 산학협력단 Pharmaceutical composition for the death of cancer origin cell
KR102315103B1 (en) * 2021-01-21 2021-10-20 주식회사 뉴캔서큐어바이오 Pharmaceutical composition for preventing or treating cancer comprising thioridazine and perhexiline as an effective ingredient

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
GB1288376A (en) 1968-10-29 1972-09-06
DE3827974A1 (en) * 1988-08-18 1990-02-22 Boehringer Mannheim Gmbh COMBINATION PREPARATIONS OF PROTEINKINASE-C INHIBITORS WITH LIPIDS, LIPID ANALOGS, CYTOSTATICA OR INHIBITORS OF PHOSPHOLIPASES
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
CH681780A5 (en) * 1991-02-25 1993-05-28 Patrinove Anticancer compsns. - consists of a cytotoxic agent with a agent to prevent multi:drug resistance, e.g. in liposome(s)
US5428051A (en) * 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
US5521189A (en) * 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) * 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) * 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
US6280768B1 (en) * 1996-07-03 2001-08-28 Prm Pharmaceuticals, Inc. Berberine alkaloids as a treatment for chronic protozoally induced diarrhea
US6008247A (en) * 1998-02-27 1999-12-28 The University Of North Carolina At Chapel Hill 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
WO1999046237A1 (en) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
ES2198139T3 (en) * 1998-08-20 2004-01-16 The University Of North Carolina At Chapel Hill DIBENZOTIOPHENE COMPOUNDS AND PROCEDURES FOR THE SAME USE.
WO2000015212A2 (en) * 1998-09-17 2000-03-23 The University Of North Carolina At Chapel Hill Antifungal activity of dicationic molecules
JP3679943B2 (en) * 1999-03-02 2005-08-03 大日本印刷株式会社 Method for producing pattern forming body
PT1231910E (en) 1999-11-16 2009-08-06 Oncozyme Pharma Inc Pentamidine for treating cancer
US6777433B2 (en) * 1999-12-22 2004-08-17 Merck Frosst Canada & Co. Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates
EP1284260A4 (en) * 2000-05-22 2004-03-31 Takeda Chemical Industries Ltd Tyrosine phosphatase inhibitors
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030161893A1 (en) * 2001-09-07 2003-08-28 Taolin Yi PTPase inhibitors and methods of using the same
BR0312597A (en) * 2002-07-11 2005-05-10 Combinatorx Inc Drug Combinations for the Treatment of Neoplasms
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
WO2005020913A2 (en) * 2003-08-25 2005-03-10 Combinatorx, Incorporated Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
BRPI0414568A (en) * 2003-09-18 2006-11-07 Combinatorx Inc drug combinations for the treatment of neoplasms
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases

Also Published As

Publication number Publication date
ES2258566T3 (en) 2006-09-01
CY1105501T1 (en) 2010-04-28
WO2002058684A3 (en) 2003-04-17
DE60117615T2 (en) 2006-11-09
US20070099906A1 (en) 2007-05-03
BG107831A (en) 2004-02-27
US6846816B2 (en) 2005-01-25
KR20030048460A (en) 2003-06-19
HRP20030460A2 (en) 2005-04-30
SK5452003A3 (en) 2004-07-07
IS6806A (en) 2003-05-05
DK1339399T3 (en) 2006-06-19
KR100720205B1 (en) 2007-05-21
CN1484525A (en) 2004-03-24
US20050192274A1 (en) 2005-09-01
PT1339399E (en) 2006-07-31
CA2436799A1 (en) 2002-08-01
US20030166642A1 (en) 2003-09-04
NO20032036D0 (en) 2003-05-06
EP1339399B1 (en) 2006-03-01
PL362690A1 (en) 2004-11-02
HUP0400529A3 (en) 2006-02-28
IL155795A0 (en) 2003-12-23
ATE318590T1 (en) 2006-03-15
TWI259077B (en) 2006-08-01
RU2286769C2 (en) 2006-11-10
AU2002246636B8 (en) 2006-01-19
AU2002246636B2 (en) 2005-12-01
NO20032036L (en) 2003-07-04
US6569853B1 (en) 2003-05-27
US7148216B2 (en) 2006-12-12
NZ525773A (en) 2005-04-29
DE60117615D1 (en) 2006-04-27
EE200300212A (en) 2003-08-15
WO2002058684A2 (en) 2002-08-01
HUP0400529A2 (en) 2004-06-28
CA2436799C (en) 2007-12-18
AR035500A1 (en) 2004-06-02
BR0115166A (en) 2003-12-30
IS2457B (en) 2008-11-15
EP1339399A2 (en) 2003-09-03
JP2004517915A (en) 2004-06-17

Similar Documents

Publication Publication Date Title
MXPA03003960A (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders.
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
WO2004006906A3 (en) Methods for the treatment of neoplasms
SG152907A1 (en) Combinations for the treatment of inflammatory disorders
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
DE59410052D1 (en) USE OF NONA AND DECAPEPTIDES FOR THE PRODUCTION OF A MEDICINAL AGAINST AIDS
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
HK1068606A1 (en) Novel aminobenzoephenones
DE69424777D1 (en) 3,4-DIARYLCHROMANE FOR TREATING DERMATITIS
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
GB0020504D0 (en) Therapeutic method
ATE275966T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACTIVIN STIMULATOR
DE60222383D1 (en) MEDICAMENT FOR THE ADMINISTRATION OF AMIFOSTIN AND RELATED ACTIVE SUBSTANCES
DE50100833D1 (en) USE OF 2-METHYL-THIAZOLIDINE-2,4-DICARBONIC ACID AND / OR ITS PHYSIOLOGICALLY COMPATIBLE SALTS FOR PRODUCING A MEDICINE FOR TREATING CANCER DISEASES
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
PL365913A1 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
YU17002A (en) Dextrazohane use in psoriasis healing
GB0122257D0 (en) Simplified sarcodictyin derivatives
UA43800A (en) Method of treating the perforated ulcer of the duodenum
UA10754A (en) Method for therapy of arterial hypertensions of various geneses

Legal Events

Date Code Title Description
FG Grant or registration